



HAL
open science

Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir

Anne-France Georgel, Delphine Cayet, Andrés Pizzorno, Manuel Rosa-Calatrava, Christophe Paget, Valentin Sencio, Jean Dubuisson, François Trottein, Jean Claude Sirard, Christophe Carnoy

► **To cite this version:**

Anne-France Georgel, Delphine Cayet, Andrés Pizzorno, Manuel Rosa-Calatrava, Christophe Paget, et al.. Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir. *Antiviral Research*, 2019, 168, pp.28-35. 10.1016/j.antiviral.2019.05.002 . inserm-02144074

HAL Id: inserm-02144074

<https://inserm.hal.science/inserm-02144074>

Submitted on 29 May 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Toll-like receptor 5 agonist flagellin reduces Influenza A Virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir

Anne-France Georgel ^{a,b}, Delphine Cayet ^a, Andrés Pizzorno ^c, Manuel Rosa-Calatrava ^{c,d}, Christophe Paget ^{a,e}, **Valentin Sencio** ^a, Jean Dubuisson ^a, François Trottein ^a, Jean-Claude Sirard ^{a,*}, Christophe Carnoy ^{a,*}

^a Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204, CIIL–Center for Infection and Immunity of Lille, Lille, France;

^b Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, France;

^c Laboratoire Virologie et Pathologie Humaine – VirPath Team, Centre International de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS UMR5308, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France

^d VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon 69008, France

^e INSERM U1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Université de Tours, France.

Keywords: Influenza A virus, TLR5, flagellin, type I interferon, interleukin 22

Declaration of interest: none

* Corresponding authors:

christophe.carnoy@univ-lille.fr and jean-claude.sirard@inserm.fr

Center for Infection and Immunity of Lille

Institut Pasteur de Lille

1, rue du Professeur Calmette

59019 Lille Cedex

FRANCE

ABSTRACT

Influenza infections remain a burden on health care systems despite vaccination programs and marketed antiviral drugs. Immunomodulation through activation of innate sensors could represent innovative approaches to fight the flu. This study evaluated the ability of flagellin, agonist of Toll-like receptor 5 (TLR5), to control the replication of influenza A virus (IAV) in mice. First, we showed that systemic or intranasal administration of flagellin activated transcription of anti-viral genes in lung tissue. **Prophylactic and therapeutic flagellin administration resulted in decreased levels of viral RNA and infectious virus in the lungs of H3N2 IAV-infected mice.** The effect of the flagellin on viral replication was also observed in *Ifnar^{-/-}* and *Il22^{-/-}* IAV-infected mice, suggesting a mechanism independent of type I interferon and interleukin 22 signaling. In addition, a combination therapy associating the neuraminidase inhibitor oseltamivir and flagellin was more effective than standalone treatments in reducing pulmonary viral **replication**. Thus, this study highlights the therapeutic potential of the flagellin to control the replication of the influenza virus.

INTRODUCTION

Influenza viruses are responsible for human seasonal epidemics and pandemic outbreaks and cause respiratory illness in humans with the potential for severe complications in young children, the elderly, immuno-compromised individuals, and patients with chronic cardiovascular or respiratory diseases. Annually, 3–5 million cases of serious illness are caused by influenza virus infections resulting in 250,000 to 500,000 deaths worldwide (Horimoto and Kawaoka, 2005). Therapeutic interventions are limited to sub-optimal vaccination and few drugs. Among them, neuraminidase inhibitors such as oseltamivir are widely used for the oral treatment of uncomplicated acute illness due to influenza but are also recommended for pre-exposure prophylaxis among at-risk individuals in contact with flu patients (Fiore et al., 2011).

Because of the narrow therapeutic window of the neuraminidase inhibitors and the recurrent emergence of drug-resistant strains, new antiviral strategies are needed (Govorkova et al., 2013). The stimulation of innate immunity could be an alternative therapeutic approach to current treatments as it induces local production of antimicrobial molecules and the recruitment of effector cells involved in controlling infection (Hancock et al., 2012; Iwasaki and Pillai, 2014). The Toll-like receptors (TLRs) are sensors of innate immunity involved in the recognition of conserved microbe-associated molecular patterns (Kawai and Akira, 2010). The activation of TLRs by microbial components triggers signaling cascades and promotes the archetypal pro-inflammatory responses involved in antimicrobial defense (Kawai and Akira, 2010). In view of their broad cellular distribution and important role in immunity, TLRs have emerged as therapeutic targets against bacterial and viral infections (Hancock et al., 2012; Savva and Roger, 2013; Hedayat et al., 2011; Mifsud et al., 2014).

In this context, experimental models showed that various agonists of TLRs could protect against influenza virus infections: agonists for TLR2, TLR3, TLR7, TLR8 and TLR9, as standalone treatments or in combination, stimulate innate immune responses able to protect against influenza A virus (IAV) infection in mammals as well as in poultry (Tan et al.,

2012; Mifsud et al., 2016; Tuvim et al., 2012; Wong et al., 2009; Lau et al., 2010; Zhao et al., 2012; Jiang et al., 2011; Norton et al., 2010; Wu et al., 2007; Hammerbeck et al., 2007; Barjesteh et al., 2015). Interestingly, most of the agonists were administered through the respiratory route as prophylaxis, indicating that the pre-stimulation of the local innate immune response can control the viral replication.

TLR5 recognizes flagellin, the structural protein of bacterial flagella and is expressed at the surface of macrophages, dendritic cells and epithelial cells. Like other TLR agonists, flagellin has immunomodulatory properties that can control numerous bacterial infections (Munoz et al., 2010; Yu et al., 2010; Jarchum et al., 2011; Kinnebrew et al., 2010; Vijayan et al., 2018). Recently, it has also been shown that repeated systemic administration of flagellin prevents rotavirus infection in mice through a mechanism dependent on interleukin 22 (IL-22) and IL-18 (Zhang et al., 2014). Prophylactic systemic administration of flagellin also protects mice against lethal infection with cytomegalovirus (Hossain et al., 2014). We recently demonstrated in mice that intranasal administration of flagellin improves the therapeutic index of antibiotics in the treatment of post-influenza virus bacterial pneumonia (Porte et al., 2015), but the role of flagellin in the control of influenza virus replication has never been studied. However, the capacity of flagellin to trigger the production of host antimicrobial molecules and the recruitment of innate cells after intranasal administration presages a role for flagellin against influenza viruses (Porte et al., 2015; Vijayan et al., 2018; Van Maele et al., 2014a).

In the present study, we analyzed the pulmonary antiviral response in mice upon respiratory or systemic flagellin administration, and tested the ability of flagellin to interfere with IAV replication. We also evaluated the role of type I interferons and IL-22 in the flagellin-mediated antiviral mechanism, as well as the potential impact of a combination of flagellin with oseltamivir on IAV production.

MATERIALS & METHODS

Mouse model of infection

Female or male C57BL/6J (6- to 12-week-old) mice (Janvier Laboratories, Saint-Berthevin, France) and female or male *Ii22^{-/-}* and *Ifnar^{-/-}* mice (backcrossed on C57BL/6J) were maintained in individually ventilated cages and handled in a vertical laminar flow cabinet (class II A2; Esco, Hatboro, PA). All experiments complied with current national and institutional regulations and ethical guidelines (B59-350009, Institut Pasteur de Lille protocol number: 2015121722376405). For the viral infection, mice were anesthetized by intraperitoneal injection of 1.25 mg of ketamine plus 0.25 mg of xylazine in 250 μ l of phosphate buffered saline (PBS), and then intranasally infected with 50 μ l of PBS containing 30 plaque forming units (PFU) of the highly pathogenic murine-adapted H3N2 influenza A virus strain Scotland/20/74 (Ivanov et al., 2013; Paget et al., 2012). **The lethal dose 50 (LD50) of the H3N2 strain is 68 PFU in C57BL/6 mice.** At selected time-points, mice were sacrificed through intraperitoneal injection of 5.47 mg of sodium pentobarbital in 100 μ l of PBS, and their lungs were aseptically recovered.

Flagellin administration

The native flagellin (FliC, GenBank accession no. **AAL20871**) was isolated from the *Salmonella enterica* Serovar Typhimurium strain SIN22, as described previously (Nempont et al., 2008; Didierlaurent et al., 2008). Using the Limulus assay (Associates of Cape Cod, Inc., East Falmouth, MA), the residual LPS concentration was determined to be < 20 pg per μ g of flagellin. To ensure that flagellin was mostly monomeric, it was heated for 10 min at 65°C before use. Flagellin was administered either intranasally (5 μ g of FliC in 30 μ l of PBS), under light anesthesia by inhalation of isoflurane (Axience, Pantin, France) either intraperitoneally (5 μ g of FliC in 200 μ l of PBS).

Oseltamivir administration

Tablets of oseltamivir phosphate (Tamiflu® 30 mg, Roche Pharma AG, Grenzach-Wyhlen, Germany) were solubilized in 1 ml of sterile water to a 30 mg/ml stock concentration, vortexed, and sonicated in a water bath at room temperature for 5 min. Mice were given oseltamivir by oral gavage once a day at 4 mg/kg/day diluted in sterile water, in a total volume of 200 µl.

Viral and murine RNA analysis

Total RNA **was** extracted with the NucleoSpin RNA II kit (Macherey-Nagel, Duren, Germany). For H3N2 RNA detection, 500 ng of total lung RNA were reverse transcribed with Superscript II Reverse Transcriptase (Invitrogen) in the presence of IAV specific primers targeting the segment 7 which encodes the matrix protein 1 (M1) (5' TCTAACCGAGGTCGAAACGTA 3'). The cDNA was amplified by Taqman real-time PCR using Taqman probe FAM-TTTGTGTTACGCTCACCGTGCC-TAMRA with forward primer: AAGACCAATCCTGTACCTCTGA and reverse primer: CAAAGCGTCTACGCTGCAGTCC. A plasmid coding the M1 gene was serially diluted to establish a standard curve (Ct values / plasmid copies) (Meyer et al., 2017). Equivalent of 12.5 ng of total lung RNA was thoroughly used to determine the level of M1 RNA in the lung of infected animals by absolute quantification (Meyer et al., 2017).

For mouse gene expression quantification, total lung RNAs were reverse transcribed with the high-capacity cDNA archive kit and random primers (Applied Biosystems, Foster City, CA). The cDNA was amplified using SYBR green-based real-time PCR using primers listed in **Supplementary Table 1**. Relative mRNA levels ($2^{-\Delta\Delta Ct}$) were determined by comparing first the PCR cycle thresholds (Ct) for the gene of interest and β -actin, the housekeeping gene (ΔCt) and second, the ΔCt values for the treated and untreated (mock) groups ($\Delta\Delta Ct$). The Ct threshold was set to 35 cycles.

PCR experiments were all performed and analyzed using a QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems).

Determination of infectious lung viral titers

For determination of the viral load in the lungs, mice were sacrificed at the indicated time point and lungs were collected, weighted and immediately frozen in liquid nitrogen. Lungs were then homogenized with an Ultra-Turrax homogenizer (IKA-Werke, Staufen, Germany), centrifuged (2500 x g, 5 min, 4°C), and the supernatants were kept at 80°C until viral titration by standard plaque assay (Hatakeyama et al., 2005). Briefly, 6 serial 10-fold dilutions of samples were prepared in Eagle's Minimum Essential Medium (EMEM, Lonza, Verviers, Belgium) complemented with trypsin 1 µg/ml, and subsequently inoculated onto confluent Madin-Darby Canine Kidney (MDCK) cell monolayers prepared in 6-well plates. After 1h incubation for viral adsorption, the inoculum was removed and wells were covered with 2 ml of overlay medium (1% Noble agar in EMEM) with trypsin 1 µg/ml. The plates were incubated at 37°C under 5% CO₂ and viral titers in plaque forming units (PFU) were determined 3 days after inoculation.

Cytokine assays

Serum IL-22 levels were measured by enzyme-linked immunosorbent assay (ELISA) following manufacturer's instructions (eBioscience, Thermo Fisher Scientific, Waltham, MA).

Statistical analysis

The results are expressed as means or medians +/- standard deviations (SD). Statistical differences were analyzed using the Mann-Whitney test or one-way ANOVA assay with Dunnett's multiple comparison test (GraphPad Prism5.0a) and were considered to be statistically significant for P values < 0.05.

RESULTS

Flagellin induces expression of anti-viral genes in the lung

Previously, microarrays were performed on lungs of C57BL/6 mice at 2, 4 and 18 h after a single intranasal administration of flagellin. Analysis of the transcriptional changes upon flagellin treatment were compared to PBS (mock)-treated animals and highlighted gene pathways related to granulocyte adhesion and diapedesis, acute phase response, or recognition of microbes through pattern recognition receptors, among others (<http://mace.ihes.fr>, accession no. **2176499768**) (Fougeron et al., 2015). The transcriptomic analysis also revealed that flagellin activates the pathways involved in antiviral responses, the impact of flagellin on these pathways **appearing to be greater at 4 h than at 2 or 18 h** (**Table 1**). We then focused on the genes involved in the different pathways and identified a set of genes which the expression significantly increased upon flagellin stimulation (fold increase > 2) (**Table 2**). Different profiles of gene expression were observed. The gene encoding for the cholesterol 25-hydroxylase (*Ch25h*), which converts cholesterol to a soluble 25-hydroxycholesterol and blocks viral fusion (Blanc et al., 2013; Liu et al., 2013) was found to be upregulated at 2 and 4 h compared to the mock group. Expression of some genes was gradually upregulated from 2 to 4 h post-treatment. This **includes** the interferon gamma inducible 47 and 204 genes (*Ifi47* and *Ifi204*) encoding antiviral GTPase and an antiviral innate immune sensor (Collazo et al., 2001; Conrady et al., 2012), and the interferon-induced transmembrane protein 5 and 6 (*Ifitm5* and *Ifitm6*) that belong to a family of inhibitors of viral entry (Huang et al., 2011; Brass et al., 2009). Finally, other genes were exclusively upregulated at 4 h post-treatment. This is the case of the genes encoding the radical S-adenosyl methionine domain containing 2 (*Rsad2*) and the interferon-stimulated gene 15 ubiquitin-like modifier (*Isg15*) which products interferes with the formation of the lipid raft during the virus budding (Wang et al., 2007) and targets newly translated viral

proteins for modification, respectively (Lenschow et al., 2007; Morales and Lenschow, 2013). For all the genes, the baseline expression was recovered after 18h indicating a transient effect of the flagellin.

The transcriptomic study was confirmed by testing the expression of the identified genes by real time qPCR, in the lung at 2 and 4 h after intranasal instillation of flagellin (**Fig. 1A**). We also analyzed the transcriptional response of the selected genes after systemic administration of flagellin (**Fig. 1B**). Interestingly, the transcriptomic response for the selected genes was globally similar between the two routes of administration, demonstrating that a systemic administration of flagellin can activate antiviral genes in the lung tissue. We also observed (i) a reduced variation in the gene expression after the systemic route compared to the intranasal route and (ii) a peak expression at 4h post-flagellin administration thus confirming the transcriptomic analysis. As expected, flagellin was able to stimulate >50-fold expression of *Ccl20* and *Saa3*, surrogate markers of effective stimulation of lung innate immunity by flagellin (Van Maele et al., 2010).

Systemic and mucosal flagellin treatment induces a decrease of influenza genomic RNA levels

We then tested in an experimental model of infection whether the flagellin-mediated antiviral transcriptomic response was associated with a decrease in IAV replication in the lung. The model consists of the intranasal inoculation of mice with a sublethal dose of H3N2 influenza A virus (IAV, 30 PFU), combined with intranasal treatments with 5 µg of flagellin (or PBS as control intervention) every 24 h, starting 12 h prior infection (**Fig. 2A**). Viral replication was followed by measuring the RNA levels of M1 genomic RNA in lung homogenates at 24, 48 and 96 h post-infection, through absolute quantification using Taqman-based real time PCR with a calibrating curve. We found an increase in H3N2 M1 RNA levels from 24 to 96 h post-infection, hence indicating efficient viral replication (**Fig. 2B**). At 48 h post-infection, the level of M1 RNA copies in lung of flagellin-treated animals was 7.3 fold lower than in mice receiving PBS, indicating an effect of the flagellin on the viral RNA replication. A similar yet

milder trend (2.3 fold decrease compared to PBS-treated mice) was also observed at 96 h post-infection (**Fig. 2B**).

As flagellin showed antiviral properties through the systemic route (Zhang et al., 2014; Hossain et al., 2014), we also treated the H3N2-infected animals with 5 µg of flagellin through the intraperitoneal route (**Fig. 2C**). Interestingly, when IAV-infected animals were treated by flagellin, we observed an 18.3 fold decrease on viral RNA levels at 48 h post-infection compared to the PBS-treated group. A significant decrease (1.9 fold) of the M1 RNA levels was also observed at 96 h post-infection in the flagellin-treated group. These results indicate that systemic administration of flagellin has a stronger effect on viral replication than intranasal administration.

The decrease of viral RNA levels upon flagellin administration is independent of type I interferon signaling

Most of the genes identified in the transcriptomic study (**Table 2**) are under the control of type I interferon (IFN α and IFN β), therefore suggesting a role of these interferons in the flagellin-mediated effect. To assess the putative role of type I IFN signaling, the levels of viral RNA were quantified after flagellin treatment in mice deficient in the type I interferon receptor (*Ifnar*^{-/-}). These mice were infected by IAV H3N2 and treated with flagellin by systemic administration before monitoring viral RNA in lungs as mentioned before (**Fig. 2A**). Flagellin induced significant 3.6 and 9 fold decrease of IAV M1 RNA at 48 and 96 h, respectively (**Fig. 3**). These results show that type I IFN signaling is not required for the flagellin-mediated reduction of IAV replication. This is also consistent with microarray data that did not indicate any upregulation of IFN α - or IFN β -specific transcripts in the lungs of flagellin-treated animals (<http://mace.ihes.fr>, accession no. 2176499768). Furthermore, systemic or respiratory administration of flagellin did not increase the pulmonary expression of *Ifnl2* or *Ifnl3* coding for type III IFN that were previously associated with influenza virus clearance in mice (data not shown) (Mordstein et al., 2008). Altogether, these results

strongly suggest that interferons are not associated with the flagellin-mediated antiviral effect.

The effect of flagellin on viral RNA replication is independent of interleukin 22 (IL-22)

Flagellin has previously been shown to protect against rotavirus intestinal infection through production of IL-22 together with IL-18 (Zhang et al., 2014). First, we found that flagellin did not stimulate *Il18* transcription in the lungs after intraperitoneal administration of flagellin both in naive and IAV-infected animals, thus ruling out the possible role of IL-18 in flagellin-mediated anti-IAV effect (**Supplementary Fig.**). We next evaluated the role of IL-22 upon flagellin-administration in the IAV respiratory infection context. We first showed that systemic administration of flagellin induced a strong production of IL-22 in the blood 2 h post administration both in non-infected and H3N2-infected animals (**Fig. 4A-B**). Strong expression of *Il22* was also observed in the lungs of naïve mice treated with flagellin (**Supplementary Fig.**). The contribution of IL-22 in the flagellin-mediated anti-viral effect was then analyzed in *Il22*^{-/-} mice by measuring the levels of viral RNA at 48 h post infection after flagellin treatments (**Fig. 4A**). As in IL-22 proficient mice, IAV RNA levels were significantly lower (7.5 fold decrease) in flagellin-treated *Il22*^{-/-} mice than in PBS-receiving *Il22*^{-/-} mice (**Fig. 4C**). These results indicate that IL-22, which is produced upon flagellin stimulation, is not required for the effect of flagellin on viral RNA production.

Systemic administration of flagellin boosts the anti-viral effect of oseltamivir

We then investigated whether the reduction of viral RNA induced by flagellin could be improved by combination with a specific virus-targeted antiviral drug such as the neuraminidase inhibitor oseltamivir. This first line antiviral agent is recommended as *per os* administration to populations exposed to IAV-infected individuals for either prophylaxis and/or therapy. Mice were treated 12 h prior H3N2 infection and then 12 and 36 h post infection with either flagellin, oseltamivir or a combination of both compounds. A group of mice received PBS as untreated control. Viral RNA replication and virus production were analyzed 48h post viral challenge (Fig. 5A). First, we found that flagellin treatment statistically decreased the infectious virus titer by 4.5 fold thus confirming the impact of flagellin on the viral RNA levels (Fig. 5B, C). Interestingly, 5 µg of intranasal flagellin was as efficient as 4 mg/ml of oral oseltamivir to control the RNA replication and IAV production. The combination of flagellin and oseltamivir significantly reduced the levels of viral RNA and viral infectious particles by 38 and 163 fold, respectively, compared to untreated animals (Fig. 5B, C). The combination therapy is also more effective at reducing RNA replication than flagellin or oseltamivir standalone treatments. We did not observe any significant reduction of the infectious particles with the combination therapy compared to the standalone treatments. However, in 50% of flagellin + oseltamivir-treated animals, PFU numbers were below the limit of detection compared to 28 % for the oseltamivir group and 0% for the flagellin group. These results suggest that a combination of flagellin and oseltamivir may enhance the antiviral effect of each compound taken separately.

DISCUSSION

Immunomodulation targeting TLR signaling represents a promising approach to control infectious diseases (Savva and Roger, 2013; Hedayat et al., 2011; Mifsud et al., 2014). In the present study, we showed for the first time that treatment of mice with the TLR5 agonist

flagellin alters influenza virus replication in the lung, independently of the route of administration (systemic or respiratory). We know from several infectious models that the biological effect of flagellin is at least in part dependent on the administration route (Vijayan et al., 2018): mucosal administration rather stimulates the epithelium, resulting in the recruitment of neutrophils and the production of antimicrobial molecules, while a systemic treatment activates dendritic cells that lead to the activation of T helper and type 3 innate lymphoid cells.

Nevertheless, the mechanism by which flagellin reduces influenza replication is yet unknown. As flagellin mainly affects viral RNA production, one can speculate that the TLR5 agonist affects the genomic transcription and replication of the influenza virus. Replication of IAV is a complex mechanism involving many host factors (Villalon-Letelier et al., 2017). It would be relevant to know whether these molecules are modulated upon flagellin stimulation and what stage(s) of the viral RNA production is impacted by flagellin (negative-sense viral RNA replication, complementary positive sense RNA production or viral RNA transcription).

Our results also reinforced the proof-of-concept that flagellin is able to trigger antiviral defenses (Zhang et al., 2014; Hossain et al., 2014). Hossain et al. showed in a model of liver colonization by the murine CMV that the decrease of viral load by flagellin correlated with the presence of NK cells suggesting a major role of these cells (Hossain et al., 2014). A detailed analysis of pulmonary cellular populations is required to evaluate the participation of NK cells but also other immune cells in flagellin-mediated control of IAV replication. In the case of rotavirus intestinal infection, Zhang et al. demonstrated that IL-22 was required for flagellin-mediated protection (Zhang et al., 2014). **IL-22 is involved in host defense mechanisms at the respiratory and intestinal mucosal surfaces and is produced after systemic administration of flagellin in mice. (Van Maele et al., 2010; Van Maele et al., 2014b; Kinnebrew et al., 2012). In our study, although we confirmed the IL-22 production after flagellin administration,** IL-22-deficient mice still managed to reduce M1 RNA upon flagellin treatment, indicating that this cytokine was dispensable for the antiviral effect of flagellin.

These results are in accordance with prior studies showing that IL-22, produced in the blood and lungs during IAV infection, is not involved in the control of the IAV replication (Guo and Topham, 2010; Ivanov et al., 2013).

Surprisingly, we also demonstrated that the effect of flagellin on viral replication was independent of type I IFN, yet recognized as the main first line of defense against viruses. This type I IFN independent anti-influenza response was also demonstrated with TLR2 agonists as well as with the association of TLR2/6 and TLR9 agonists, hence suggesting that antiviral pathways induced through stimulation of these TLRs and TLR5 are independent of the canonical IFN response (Tan et al., 2012; Tuvim et al., 2012). Nevertheless, we found that flagellin activates several **interferon-stimulated genes (ISG)**, which may indicate the possibility of a TLR5-dependent, interferon-independent activation of these genes.

We previously showed that administration of flagellin through the respiratory tract could improve the therapeutic index of antibiotics in the context of pneumococcal infection and post-IAV bacterial pneumonia (Porte et al., 2015). Here, we demonstrated that the combination of flagellin and oseltamivir strongly decreases the level of viral M1 RNA, significantly enhancing the antiviral effect of each standalone treatment. In that regard, the effect of a therapy combining a TLR agonist and a specific influenza-targeted antiviral molecule like oseltamivir has been described elsewhere. Indeed, Lau et al. showed that co-administration of TLR3 agonist with oseltamivir reduced pulmonary viral titers of mice infected with H5N1 virus, compared to oseltamivir alone (Lau et al., 2010). More recently, Leiva-Suarez et al. reported that aerosol administration of TLR2/6 and TLR9 agonists associated with oseltamivir improved mouse survival after lethal influenza A pneumonia (Leiva-Juarez et al., 2018). Altogether, our data contribute to highlight the therapeutic potential of the association of molecules with distinct modes of action : a neuraminidase inhibitor with a direct effect on viral infectivity but with a narrow therapeutic window, and stimulators of innate immunity acting on host cells by inducing antiviral pathways with longer lasting effect.

ACKNOWLEDGMENTS

This work was funded by INSERM, CNRS, Institut Pasteur de Lille, University of Lille and Inserm-Transfert (CoPoC grant “Innatebiotic”). We thank Dr R. Le Goffic for providing the plasmid used for the viral RNA quantification.

REFERENCES

- Barjesteh, N., Shojadoost, B., Brisbin, J. T., Emam, M., Hodgins, D.C., Nagy, E., Sharif, S., 2015. Reduction of avian influenza virus shedding by administration of Toll-like receptor ligands to chickens. *Vaccine* 33, 4843-9.
- Blanc, M., Hsieh, W.Y., Robertson, K.A., Kropp, K.A., Forster, T., Shui, G., Lacaze, P., Watterson, S., Griffiths, S.J., Spann, N.J., Meljon, A., Talbot, S., Krishnan, K., Covey, D.F., Wenk, M.R., Craigon, M., Ruzsics, Z., Haas, J., Angulo, A., Griffiths, W.J., Glass, C.K., Wang, Y., Ghazal, P., 2013. The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. *Immunity* 38, 106-18.
- Brass, A.L., Huang, I.C., Benita, Y., John, S.P., Krishnan, M.N., Feeley, E.M., Ryan, B.J., Weyer, J.L., van der Weyden, L., Fikrig, E., Adams, D.J., Xavier, R.J., Farzan, M., Elledge, S.J., 2009. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. *Cell* 139, 1243-54.
- Collazo, C.M., Yap, G.S., Sempowski, G.D., Lusby, K.C., Tessarollo, L., Vande Woude, G.F., Sher, A., Taylor, G.A., 2001. Inactivation of LRG-47 and IRG-47 reveals a family of interferon gamma-inducible genes with essential, pathogen-specific roles in resistance to infection. *J Exp Med* 194, 181-8.
- Conrady, C.D., Zheng, M., Fitzgerald, K.A., Liu, C., Carr, D.J., 2012. Resistance to HSV-1 infection in the epithelium resides with the novel innate sensor, IFI-16. *Mucosal Immunol* 5, 173-83.
- Didierlaurent, A., Goulding, J., Patel, S., Snelgrove, R., Low, L., Bebien, M., Lawrence, T., van Rijt, L.S., Lambrecht, B.N., Sirard, J.C., Hussell, T., 2008. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. *J Exp Med* 205, 323-9.
- Fiore, A.E., Fry, A., Shay, D., Gubareva, L., Bresee, J.S., Uyeki, T. M., 2011. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 60, 1-24.
- Fougeron, D., Van Maele, L., Songhet, P., Cayet, D., Hot, D., Van Rooijen, N., Mollenkopf, H.J., Hardt, W.D., Benecke, A.G., Sirard, J.C., 2015. Indirect Toll-like receptor 5-mediated activation of conventional dendritic cells promotes the mucosal adjuvant activity of flagellin in the respiratory tract. *Vaccine* 33, 3331-41.
- Furuse, Y., Suzuki, A., Kamigaki, T., Oshitani, H., 2009. Evolution of the M gene of the influenza A virus in different host species: large-scale sequence analysis. *Virol J* 6, 67.

- Govorkova, E.A., Baranovich, T., Seiler, P., Armstrong, J., Burnham, A., Guan, Y., Peiris, M., Webby, R.J., Webster, R.G., 2013. Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. *Antiviral Res* 98, 297-304.
- Guo, H. and Topham, D.J., 2010. Interleukin-22 (IL-22) production by pulmonary Natural Killer cells and the potential role of IL-22 during primary influenza virus infection. *J Virol* 84, 7750-9
- Hammerbeck, D.M., Bureson, G.R., Schuller, C.J., Vasilakos, J.P., Tomai, M., Egging, E., Cochran, F.R., Woulfe, S., Miller, R.L., 2007. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. *Antiviral Res* 73, 1-11.
- Hancock, R.E., Nijnik, A., Philpott, D.J., 2012. Modulating immunity as a therapy for bacterial infections. *Nat Rev Microbiol* 10, 243-54.
- Hatakeyama, S., Sakai-Tagawa, Y., Kiso, M., Goto, H., Kawakami, C., Mitamura, K., Sugaya, N., Suzuki, Y., Kawaoka, Y., 2005. Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. *J Clin Microbiol.* 43, 4139-46.
- Hedayat, M., Netea, M.G., Rezaei, N., 2011. Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. *Lancet Infect Dis* 11, 702-12.
- Horimoto, T., Kawaoka, Y., 2005. Influenza: lessons from past pandemics, warnings from current incidents. *Nat Rev Microbiol* 3, 591-600.
- Hossain, M.S., Ramachandiran, S., Gewirtz, A.T., Waller, E.K., 2014. Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice. *PLoS One* 9, e96165.
- Huang, I.C., Bailey, C.C., Weyer, J.L., Radoshitzky, S.R., Becker, M.M., Chiang, J.J., Brass, A.L., Ahmed, A.A., Chi, X., Dong, L., Longobardi, L.E., Boltz, D., Kuhn, J.H., Elledge, S.J., Bavari, S., Denison, M.R., Choe, H., Farzan, M., 2011. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. *PLoS Pathog* 7, e1001258.
- Ivanov, S., Renneson, J., Fontaine, J., Barthelemy, A., Paget, C., Fernandez, E.M., Blanc, F., De Trez, C., Van Maele, L., Dumoutier, L., Huerre, M.R., Eberl, G., Si-Tahar, M., Gosset, P., Renauld, J.C., Sirard, J.C., Faveeuw, C., Trottein, F., 2013. Interleukin-22 reduces lung inflammation during influenza A virus infection and protects against secondary bacterial infection. *J Virol* 87, 6911-24.
- Iwasaki, A., Pillai, P.S., 2014. Innate immunity to influenza virus infection. *Nat Rev Immunol* 14, 315-28.
- Jarchum, I., Liu, M., Lipuma, L., Pamer, E.G., 2011. Toll-like receptor 5 stimulation protects mice from acute *Clostridium difficile* colitis. *Infect Immun* 79, 1498-503.

- Jiang, T., Zhao, H., Li, X.F., Deng, Y.Q., Liu, J., Xu, L.J., Han, J.F., Cao, R.Y., Qin, E.D., Qin, C.F., 2011. CpG oligodeoxynucleotides protect against the 2009 H1N1 pandemic influenza virus infection in a murine model. *Antiviral Res* 89, 124-6.
- Kawai, T., Akira, S., 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat Immunol* 11, 373-84.
- Kinnebrew, M.A., Ubeda, C., Zenewicz, L.A., Smith, N., Flavell, R.A., Pamer, E.G., 2010. Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-resistant *Enterococcus* infection. *J Infect Dis* 201, 534-43.
- Kinnebrew, M.A., Buffie, C.G., Diehl, G.E., Zenewicz, L.A., Leiner, I., Hohl, T.M., Flavell, R.A., Littman, D.R., Pamer, E.G., 2012. Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. *Immunity* 36, 276-87.
- Lau, Y.F., Tang, L.H., Ooi, E.E., Subbarao, K., 2010. Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. *Virology* 406, 80-7.
- Leiva-Juarez, M.M., Kirkpatrick, C.T., Gilbert, B.E., Scott, B., Tuvim, M.J., Dickey, B.F., Evans, S.E., Markesich, D., 2018. Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir. *Eur J Pharmacol* 818, 191-197.
- Lenschow, D.J., Lai, C., Frias-Staheli, N., Giannakopoulos, N.V., Lutz, A., Wolff, T., Osiak, A., Levine, B., Schmidt, R.E., Garcia-Sastre, A., Leib, D.A., Pekosz, A., Knobeloch, K. P., Horak, I., Virgin, H.W.t., 2007. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. *Proc Natl Acad Sci U S A* 104, 1371-6.
- Liu, S.Y., Aliyari, R., Chikere, K., Li, G., Marsden, M.D., Smith, J.K., Pernet, O., Guo, H., Nusbaum, R., Zack, J.A., Freiberg, A.N., Su, L., Lee, B., Cheng, G., 2013. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. *Immunity* 38, 92-105.
- Meyer, L., Leymarie, O., Chevalier, C., Esnault, E., Moroldo, M., Da Costa, B., Georgeault, S., Roingeard, P., Delmas, B., Quere, P., Le Goffic, R., 2017. Transcriptomic profiling of a chicken lung epithelial cell line (CLEC213) reveals a mitochondrial respiratory chain activity boost during influenza virus infection. *PLoS One* 12, e0176355.
- Mifsud, E.J., Tan, A. C., Jackson, D.C., 2014. TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease. *Front Immunol* 5, 79.

- Mifsud, E.J., Tan, A.C., Reading, P.C., Jackson, D.C., 2016. Mapping the pulmonary environment of animals protected from virulent H1N1 influenza infection using the TLR-2 agonist Pam(2)Cys. *Immunol Cell Biol* 94, 169-76.
- Morales, D.J., Lenschow, D.J., 2013. The antiviral activities of ISG15. *J Mol Biol* 425, 4995-5008.
- Mordstein, M., Kochs, G., Dumoutier, L., Renauld, J. ., Paludan, S.R., Klucher, K., Staeheli, P., 2008. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. *PLoS Pathog* 4, e1000151.
- Munoz, N., Van Maele, L., Marques, J.M., Rial, A., Sirard, J.C., Chabalgoity, J.A., 2010. Mucosal administration of flagellin protects mice from *Streptococcus pneumoniae* lung infection. *Infect Immun* 78, 4226-33.
- Nempont, C., Cayet, D., Rumbo, M., Bompard, C., Villeret, V., Sirard, J.C., 2008. Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. *J Immunol* 181, 2036-43.
- Norton, E.B., Clements, J.D., Voss, T.G., Cardenas-Freytag, L., 2010. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. *J Virol* 84, 2983-95.
- Paget, C., Ivanov, S., Fontaine, J., Renneson, J., Blanc, F., Pichavant, M., Dumoutier, L., Ryffel, B., Renauld, J.C., Gosset, P., Gosset, P., Si-Tahar, M., Faveeuw, C., Trottein, F., 2012. Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza A virus infection: potential role in protection against lung epithelial damages. *J Biol Chem* 287, 8816-29.
- Porte, R., Fougeron, D., Munoz-Wolf, N., Tabareau, J., Georgel, A.F., Wallet, F., Paget, C., Trottein, F., Chabalgoity, J.A., Carnoy, C., Sirard, J.C., 2015. A Toll-Like Receptor 5 Agonist Improves the Efficacy of Antibiotics in Treatment of Primary and Influenza Virus-Associated Pneumococcal Mouse Infections. *Antimicrob Agents Chemother* 59, 6064-72.
- Rossman, J.S., Lamb, R.A., 2011. Influenza virus assembly and budding. *Virology* 411, 229-36.
- Savva, A., Roger, T., 2013. Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. *Front Immunol* 4, 387.
- Tan, A.C., Mifsud, E.J., Zeng, W., Edenborough, K., McVernon, J., Brown, L.E., Jackson, D. C., 2012. Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice. *Mol Pharm* 9, 2710-8.
- Tuvim, M.J., Gilbert, B.E., Dickey, B.F., Evans, S.E., 2012. Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. *PLoS One* 7, e30596.

- Van Maele, L., Carnoy, C., Cayet, D., Songhet, P., Dumoutier, L., Ferrero, I., Janot, L., Erard, F., Bertout, J., Leger, H., Sebbane, F., Benecke, A., Renauld, J.C., Hardt, W.D., Ryffel, B., Sirard, J.C., 2010. TLR5 signaling stimulates the innate production of IL-17 and IL-22 by CD3(neg)CD127+ immune cells in spleen and mucosa. *J Immunol* 185, 1177-85.
- Van Maele, L., Fougeron, D., Janot, L., Didierlaurent, A., Cayet, D., Tabareau, J., Rumbo, M., Corvo-Chamaillard, S., Boulenouar, S., Jeffs, S., Vande Walle, L., Lamkanfi, M., Lemoine, Y., Erard, F., Hot, D., Hussell, T., Ryffel, B., Benecke, A.G., Sirard, J.C., 2014a. Airway structural cells regulate TLR5-mediated mucosal adjuvant activity. *Mucosal Immunol* 7, 489-500.
- Van Maele, L., Carnoy, C., Cayet, D., Ivanov, S., Porte, R., Deruy, E., Chabalgoity, J.A., Renauld, J.C., Eberl, G., Benecke, A.G., Trottein, F., Faveeuw, C., Sirard, J.C., 2014b. Activation of Type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during *Streptococcus pneumoniae* infection. *J Infect Dis* 210, 493-503.
- Vijayan, A., Rumbo, M., Carnoy, C., Sirard, J.C., 2018. Compartmentalized Antimicrobial Defenses in Response to Flagellin. *Trends Microbiol* 26, 423-435.
- Villalon-Letelier, F., Brooks, A. G., Saunders, P.M., Londrigan, S.L., Reading, P.C., 2017. Host Cell Restriction Factors that Limit Influenza A Infection. *Viruses* 9.
- Wang, X., Hinson, E.R., Cresswell, P., 2007. The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. *Cell Host Microbe* 2, 96-105.
- Wong, J.P., Christopher, M.E., Viswanathan, S., Karpoff, N., Dai, X., Das, D., Sun, L.Q., Wang, M., Salazar, A. M., 2009. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. *Vaccine* 27, 3481-3.
- Wu, C.C., Hayashi, T., Takabayashi, K., Sabet, M., Smee, D.F., Guiney, D.D., Cottam, H. B., Carson, D.A., 2007. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. *Proc Natl Acad Sci U S A* 104, 3990-5.
- Yu, F.S., Cornicelli, M.D., Kovach, M.A., Newstead, M.W., Zeng, X., Kumar, A., Gao, N., Yoon, S.G., Gallo, R.L., Standiford, T.J., 2010. Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. *J Immunol* 185, 1142-9.
- Zhang, B., Chassaing, B., Shi, Z., Uchiyama, R., Zhang, Z., Denning, T.L., Crawford, S. E., Pruijssers, A.J., Iskarpatyoti, J.A., Estes, M.K., Dermody, T.S., Ouyang, W., Williams, I.R., Vijay-Kumar, M., Gewirtz, A.T., 2014. Viral infection. Prevention and cure of rotavirus infection via TLR5/NLRC4-mediated production of IL-22 and IL-18. *Science* 346, 861-5.

Zhao, J., Wohlford-Lenane, C., Zhao, J., Fleming, E., Lane, T.E., McCray, P.B., Jr., Perlman, S., 2012. Intranasal treatment with poly(I*C) protects aged mice from lethal respiratory virus infections. *J Virol* 86, 11416-24.

FIGURE LEGENDS

Figure 1: Intranasal or systemic administration of flagellin activates antiviral genes in the lung. C57BL/6 male mice (n=4) were treated intranasally (A) or intraperitoneally (B) with 5 µg of flagellin in phosphate-buffered saline. Lungs were sampled at 2h and 4h and mRNA was quantified by qRT-PCR. Relative expression was normalized to the expression of mock animals (arbitrarily set to a value of 1). Results are represented as the mean. Statistical significance relative to mock group was assessed by one-way ANOVA with Dunnett's multiple comparison test (*: P <0,05 ; **: P <0,01, ***: P <0.001)

Figure 2: Systemic and mucosal administration of flagellin altered viral RNA replication in the lung.

(A) Male C57BL/6 mice (n=5 to 6) were infected intranasally with H3N2 (30 PFU). Twelve hours before infection and 12, 36, 60 and 84 h post-infection, mice received 5 µg of flagellin intranasally (B) or intraperitoneally (C). Lungs were sampled 24, 48 or 96 h post infection for viral RNA quantification using quantitative RT-PCR. Values correspond to the absolute copy number of the M1 viral RNA / 12.5 ng of total lung RNA. The solid line corresponds to the median value and the dashed line represents the detection threshold. A representative experiment out of two is shown. Statistical significance was assessed by Mann-Whitney test (**: P <0,01).

Figure 3: The type I interferon pathway is not required for the flagellin-mediated effect on viral RNA production. *Ifnar*^{-/-} mice (n=4 to 6) were infected intranasally with H3N2 (30 PFU) and treated intraperitoneally with 5 µg of flagellin twelve hours before infection and 12, 36, 60 and 84 h post-infection. Lungs were sampled 48 and 96 h post infection for viral RNA quantification using quantitative RT-PCR. Values correspond to the absolute copy number of the M1 viral RNA / 12.5 ng of total lung RNA. The solid line corresponds to the

median value and the dashed line represents the detection threshold. Statistical significance was assessed by Mann-Whitney test (*: $P < 0.05$; **: $P < 0.01$)

Figure 4 : IL-22 is not required for flagellin-mediated decrease of viral H3N2 M1 RNA levels. (A) Male C57BL/6 or *Il22*^{-/-} mice (n = 7) were infected intranasally with H3N2 (30 PFU). Twelve hours before infection and 12 and 36h post-infection, mice received intraperitoneally 5 µg of flagellin or PBS as control. (B) Blood was sampled in C57BL/6 mice 10 h before infection and 38 h post-viral challenge for serum cytokine analysis. IL-22 levels in serum were measured by ELISA. Results are given as mean with standard deviation. **As expected IL-22 was not detected in *Il22*^{-/-} mice (data not shown).** Statistical significance (**: $P < 0.01$) compared to PBS-treated group was assessed by Mann-Whitney test. (C) Lungs were sampled at 48 h post-infection for viral **RNA** quantification using quantitative RT-PCR. Values correspond to the absolute copy number of M1 viral RNA / 12.5 ng of total lung RNA. The solid line corresponds to the median value and the dashed line represents the detection threshold. One representative experiment out of two is shown. Statistical significance was assessed by Mann-Whitney test (**: $P < 0.01$, ***: $P < 0.001$).

Figure 5 : Systemic administration of flagellin boosts the effect of oseltamivir

(A) Male C57BL/6 mice (n = 11) were infected intranasally with H3N2 (30 PFU). Twelve hours before infection and 12 and 36 h post-infection, mice received either 5 µg of flagellin intraperitoneally, 4 mg/kg of oseltamivir (OSL 4) intragastrically, or a combination of flagellin with oseltamivir. **A group of mice was left untreated (PBS). Lungs were sampled 48 h post infection.** (B) **Viral RNA quantification using quantitative RT-PCR. Values correspond to the absolute copy number of M1 viral RNA / 12.5 ng of total lung RNA.** (C) **Infectious viral titers defined as plaque forming units (PFU) / g of lung tissue. The solid line corresponds to the median value. The dashed line represents the detection threshold. Statistical significance was assessed by Mann-Whitney test (*: $P < 0.05$; **: $P < 0.01$; ***: $P < 0.001$).**

Highlights for “***Toll-like receptor 5 agonist flagellin reduces Influenza A Virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir***”

- Flagellin, agonist of Toll-like receptor 5 (TLR5), induces expression of anti-viral genes in lungs.
- Systemic and mucosal flagellin treatment reduces of influenza A virus replication in mice.
- The decrease of IAV RNA levels upon flagellin administration is independent of type I interferon and IL-22 signaling.
- Systemic administration of flagellin boosts the anti-viral effect of oseltamivir.

1
2
3
4 **Toll-like receptor 5 agonist flagellin reduces Influenza A**
5 **Virus replication independently of type I interferon and**
6 **interleukin 22 and improves antiviral efficacy of**
7 **oseltamivir**
8
9
10
11
12

13 Anne-France Georgel ^{a,b}, Delphine Cayet ^a, Andrés Pizzorno ^c, Manuel
14 Rosa-Calatrava ^{c,d}, Christophe Paget ^{a,e}, Valentin Sencio ^a, Jean
15 Dubuisson ^a, François Trottein ^a, Jean-Claude Sirard ^{a,*}, Christophe
16 Carnoy ^{a,*}
17
18
19
20
21

22 ^a Univ. Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204,
23 CIIL–Center for Infection and Immunity of Lille, Lille, France;
24

25 ^b Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, France;
26

27 ^c Laboratoire Virologie et Pathologie Humaine – VirPath Team, Centre International
28 de Recherche en Infectiologie (CIRI), Inserm U1111, CNRS UMR5308, Ecole
29 Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Université de
30 Lyon, Lyon, France
31

32 ^d VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1,
33 Université de Lyon, Lyon 69008, France
34

35 ^e INSERM U1100, Centre d'Etude des Pathologies Respiratoires (CEPR), Université de
36 Tours, France.
37

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
Keywords: Influenza A virus, TLR5, flagellin, type I interferon, interleukin 22

Declaration of interest: none

* Corresponding authors:

christophe.carnoy@univ-lille.fr and jean-claude.sirard@inserm.fr

Center for Infection and Immunity of Lille

Institut Pasteur de Lille

1, rue du Professeur Calmette

59019 Lille Cedex

60
61
62 FRANCE

63
64 **ABSTRACT**

65
66 Influenza infections remain a burden on health care systems despite vaccination programs
67
68 and marketed antiviral drugs. Immunomodulation through activation of innate sensors could
69
70 represent innovative approaches to fight the flu. This study evaluated the ability of flagellin,
71
72 agonist of Toll-like receptor 5 (TLR5), to control the replication of influenza A virus (IAV) in
73
74 mice. First, we showed that systemic or intranasal administration of flagellin activated
75
76 transcription of anti-viral genes in lung tissue. Prophylactic and therapeutic flagellin
77
78 administration resulted in decreased levels of viral RNA and infectious virus in the lungs of
79
80 H3N2 IAV-infected mice. The effect of the flagellin on viral replication was also observed in
81
82 *Ifnar*^{-/-} and *Il22*^{-/-} IAV-infected mice, suggesting a mechanism independent of type I
83
84 interferon and interleukin 22 signaling. In addition, a combination therapy associating the
85
86 neuraminidase inhibitor oseltamivir and flagellin was more effective than standalone
87
88 treatments in reducing pulmonary viral replication. Thus, this study highlights the
89
90 therapeutic potential of the flagellin to control the replication of the influenza virus.
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118

119
120
121 **INTRODUCTION**
122

123 Influenza viruses are responsible for human seasonal epidemics and pandemic
124 outbreaks and cause respiratory illness in humans with the potential for severe
125 complications in young children, the elderly, immuno-compromised individuals, and patients
126 with chronic cardiovascular or respiratory diseases. Annually, 3–5 million cases of serious
127 illness are caused by influenza virus infections resulting in 250,000 to 500,000 deaths
128 worldwide (Horimoto and Kawaoka, 2005). Therapeutic interventions are limited to sub-
129 optimal vaccination and few drugs. Among them, neuraminidase inhibitors such as
130 oseltamivir are widely used for the oral treatment of uncomplicated acute illness due to
131 influenza but are also recommended for pre-exposure prophylaxis among at-risk individuals
132 in contact with flu patients (Fiore et al., 2011).
133
134
135
136
137
138
139
140
141
142

143 Because of the narrow therapeutic window of the neuraminidase inhibitors and the
144 recurrent emergence of drug-resistant strains, new antiviral strategies are needed
145 (Govorkova et al., 2013). The stimulation of innate immunity could be an alternative
146 therapeutic approach to current treatments as it induces local production of antimicrobial
147 molecules and the recruitment of effector cells involved in controlling infection (Hancock et
148 al., 2012; Iwasaki and Pillai, 2014). The Toll-like receptors (TLRs) are sensors of innate
149 immunity involved in the recognition of conserved microbe-associated molecular patterns
150 (Kawai and Akira, 2010). The activation of TLRs by microbial components triggers signaling
151 cascades and promotes the archetypal pro-inflammatory responses involved in
152 antimicrobial defense (Kawai and Akira, 2010). In view of their broad cellular distribution
153 and important role in immunity, TLRs have emerged as therapeutic targets against bacterial
154 and viral infections (Hancock et al., 2012; Savva and Roger, 2013; Hedayat et al., 2011;
155 Mifsud et al., 2014).
156
157
158
159
160
161
162
163
164
165
166
167

168 In this context, experimental models showed that various agonists of TLRs could
169 protect against influenza virus infections: agonists for TLR2, TLR3, TLR7, TLR8 and TLR9,
170 as standalone treatments or in combination, stimulate innate immune responses able to
171 protect against influenza A virus (IAV) infection in mammals as well as in poultry (Tan et al.,
172
173
174
175
176
177

178
179
180 2012; Mifsud et al., 2016; Tuvim et al., 2012; Wong et al., 2009; Lau et al., 2010; Zhao et
181
182 al., 2012; Jiang et al., 2011; Norton et al., 2010; Wu et al., 2007; Hammerbeck et al., 2007;
183
184 Barjesteh et al., 2015). Interestingly, most of the agonists were administrated through the
185
186 respiratory route as prophylaxis, indicating that the pre-stimulation of the local innate
187
188 immune response can control the viral replication.

189
190 TLR5 recognizes flagellin, the structural protein of bacterial flagella and is expressed
191
192 at the surface of macrophages, dendritic cells and epithelial cells. Like other TLR agonists,
193
194 flagellin has immunomodulatory properties that can control numerous bacterial infections
195
196 (Munoz et al., 2010; Yu et al., 2010; Jarchum et al., 2011; Kinnebrew et al., 2010; Vijayan
197
198 et al., 2018). Recently, it has also been shown that repeated systemic administration of
199
200 flagellin prevents rotavirus infection in mice through a mechanism dependent on interleukin
201
202 22 (IL-22) and IL-18 (Zhang et al., 2014). Prophylactic systemic administration of flagellin
203
204 also protects mice against lethal infection with cytomegalovirus (Hossain et al., 2014). We
205
206 recently demonstrated in mice that intranasal administration of flagellin improves the
207
208 therapeutic index of antibiotics in the treatment of post-influenza virus bacterial pneumonia
209
210 (Porte et al., 2015), but the role of flagellin in the control of influenza virus replication has
211
212 never been studied. However, the capacity of flagellin to trigger the production of host
213
214 antimicrobial molecules and the recruitment of innate cells after intranasal administration
215
216 presages a role for flagellin against influenza viruses (Porte et al., 2015; Vijayan et al., 2018;
217
218 Van Maele et al., 2014a).

219
220 In the present study, we analyzed the pulmonary antiviral response in mice upon
221
222 respiratory or systemic flagellin administration, and tested the ability of flagellin to interfere
223
224 with IAV replication. We also evaluated the role of type I interferons and IL-22 in the flagellin-
225
226 mediated antiviral mechanism, as well as the potential impact of a combination of flagellin
227
228 with oseltamivir on IAV production.

MATERIALS & METHODS

Mouse model of infection

Female or male C57BL/6J (6- to 12-week-old) mice (Janvier Laboratories, Saint-Berthevin, France) and female or male *Ii22^{-/-}* and *Ifnar^{-/-}* mice (backcrossed on C57BL/6J) were maintained in individually ventilated cages and handled in a vertical laminar flow cabinet (class II A2; Esco, Hatboro, PA). All experiments complied with current national and institutional regulations and ethical guidelines (B59-350009, Institut Pasteur de Lille protocol number: 2015121722376405). For the viral infection, mice were anesthetized by intraperitoneal injection of 1.25 mg of ketamine plus 0.25 mg of xylazine in 250 μ l of phosphate buffered saline (PBS), and then intranasally infected with 50 μ l of PBS containing 30 plaque forming units (PFU) of the highly pathogenic murine-adapted H3N2 influenza A virus strain Scotland/20/74 (Ivanov et al., 2013; Paget et al., 2012). The lethal dose 50 (LD50) of the H3N2 strain is 68 PFU in C57BL/6 mice. At selected time-points, mice were sacrificed through intraperitoneal injection of 5.47 mg of sodium pentobarbital in 100 μ l of PBS, and their lungs were aseptically recovered.

Flagellin administration

The native flagellin (FliC, GenBank accession no. [AAL20871](#)) was isolated from the *Salmonella enterica* Serovar Typhimurium strain SIN22, as described previously (Nempont et al., 2008; Didierlaurent et al., 2008). Using the Limulus assay (Associates of Cape Cod, Inc., East Falmouth, MA), the residual LPS concentration was determined to be < 20 pg per μ g of flagellin. To ensure that flagellin was mostly monomeric, it was heated for 10 min at 65°C before use. Flagellin was administered either intranasally (5 μ g of FliC in 30 μ l of PBS), under light anesthesia by inhalation of isoflurane (Axience, Pantin, France) either intraperitoneally (5 μ g of FliC in 200 μ l of PBS).

296
297
298
299
300 **Oseltamivir administration**
301

302 Tablets of oseltamivir phosphate (Tamiflu® 30 mg, Roche Pharma AG, Grenzach-Wyhlen,
303 Germany) were solubilized in 1 ml of sterile water to a 30 mg/ml stock concentration,
304 vortexed, and sonicated in a water bath at room temperature for 5 min. Mice were given
305 oseltamivir by oral gavage once a day at 4 mg/kg/day diluted in sterile water, in a total
306 volume of 200 µl.
307

308
309
310
311
312
313 **Viral and murine RNA analysis**
314

315 Total RNA was extracted with the NucleoSpin RNA II kit (Macherey-Nagel, Duren,
316 Germany). For H3N2 RNA detection, 500 ng of total lung RNA were reverse transcribed
317 with Superscript II Reverse Transcriptase (Invitrogen) in the presence of IAV specific
318 primers targeting the segment 7 which encodes the matrix protein 1 (M1) (5'
319 TCTAACCGAGGTCGAAACGTA 3'). The cDNA was amplified by Taqman real-time PCR
320 using Taqman probe FAM-TTTGTGTTACGCTCACCGTGCC-TAMRA with forward
321 primer: AAGACCAATCCTGTACCTCTGA and reverse primer:
322 CAAAGCGTCTACGCTGCAGTCC. A plasmid coding the M1 gene was serially diluted to
323 establish a standard curve (Ct values / plasmid copies) (Meyer et al., 2017). Equivalent of
324 12.5 ng of total lung RNA was thoroughly used to determine the level of M1 RNA in the lung
325 of infected animals by absolute quantification (Meyer et al., 2017).
326
327

328 For mouse gene expression quantification, total lung RNAs were reverse transcribed with
329 the high-capacity cDNA archive kit and random primers (Applied Biosystems, Foster City,
330 CA). The cDNA was amplified using SYBR green-based real-time PCR using primers listed
331 in **Supplementary Table 1**. Relative mRNA levels ($2^{-\Delta\Delta Ct}$) were determined by comparing
332 first the PCR cycle thresholds (Ct) for the gene of interest and β -actin, the housekeeping
333 gene (ΔCt) and second, the ΔCt values for the treated and untreated (mock) groups ($\Delta\Delta Ct$).
334 The Ct threshold was set to 35 cycles.
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354

355
356
357 PCR experiments were all performed and analyzed using a QuantStudio 12K Flex Real-
358
359 Time PCR System (Applied Biosystems).
360
361

362 363 **Determination of infectious lung viral titers**

364
365 For determination of the viral load in the lungs, mice were sacrificed at the indicated time
366
367 point and lungs were collected, weighted and immediately frozen in liquid nitrogen. Lungs
368
369 were then homogenized with an Ultra-Turrax homogenizer (IKA-Werke, Staufen, Germany),
370
371 centrifuged (2500 x g, 5 min, 4°C), and the supernatants were kept at 80°C until viral titration
372
373 by standard plaque assay (Hatakeyama et al., 2005). Briefly, 6 serial 10-fold dilutions of
374
375 samples were prepared in Eagle's Minimum Essential Medium (EMEM, Lonza, Verviers,
376
377 Belgium) complemented with trypsin 1 µg/ml, and subsequently inoculated onto confluent
378
379 Madin-Darby Canine Kidney (MDCK) cell monolayers prepared in 6-well plates. After 1h
380
381 incubation for viral adsorption, the inoculum was removed and wells were covered with 2
382
383 ml of overlay medium (1% Noble agar in EMEM) with trypsin 1 µg/ml. The plates were
384
385 incubated at 37°C under 5% CO₂ and viral titers in plaque forming units (PFU) were
386
387 determined 3 days after inoculation.
388
389

390 391 **Cytokine assays**

392
393 Serum IL-22 levels were measured by enzyme-linked immunosorbent assay (ELISA)
394
395 following manufacturer's instructions (eBioscience, Thermo Fisher Scientific, Waltham,
396
397 MA).
398
399
400

401 402 **Statistical analysis**

403
404 The results are expressed as means or medians +/- standard deviations (SD). Statistical
405
406 differences were analyzed using the Mann-Whitney test or one-way ANOVA assay with
407
408 Dunnett's multiple comparison test (GraphPad Prism5.0a) and were considered to be
409
410 statistically significant for P values < 0.05.
411
412
413

RESULTS

Flagellin induces expression of anti-viral genes in the lung

Previously, microarrays were performed on lungs of C57BL/6 mice at 2, 4 and 18 h after a single intranasal administration of flagellin. Analysis of the transcriptional changes upon flagellin treatment were compared to PBS (mock)-treated animals and highlighted gene pathways related to granulocyte adhesion and diapedesis, acute phase response, or recognition of microbes through pattern recognition receptors, among others (<http://mace.ihes.fr>, accession no. **2176499768**) (Fougeron et al., 2015). The transcriptomic analysis also revealed that flagellin activates the pathways involved in antiviral responses, the impact of flagellin on these pathways appearing to be greater at 4 h than at 2 or 18 h (**Table 1**). We then focused on the genes involved in the different pathways and identified a set of genes which the expression significantly increased upon flagellin stimulation (fold increase > 2) (**Table 2**). Different profiles of gene expression were observed. The gene encoding for the cholesterol 25-hydroxylase (*Ch25h*), which converts cholesterol to a soluble 25-hydroxycholesterol and blocks viral fusion (Blanc et al., 2013; Liu et al., 2013) was found to be upregulated at 2 and 4 h compared to the mock group. Expression of some genes was gradually upregulated from 2 to 4 h post-treatment. This includes the interferon gamma inducible 47 and 204 genes (*Ifi47* and *Ifi204*) encoding antiviral GTPase and an antiviral innate immune sensor (Collazo et al., 2001; Conrady et al., 2012), and the interferon-induced transmembrane protein 5 and 6 (*Ifitm5* and *Ifitm6*) that belong to a family of inhibitors of viral entry (Huang et al., 2011; Brass et al., 2009). Finally, other genes were exclusively upregulated at 4 h post-treatment. This is the case of the genes encoding the radical S-adenosyl methionine domain containing 2 (*Rsad2*) and the interferon-stimulated gene 15 ubiquitin-like modifier (*Isg15*) which products interferes with the formation of the lipid raft during the virus budding (Wang et al., 2007) and targets newly translated viral

473
474
475 proteins for modification, respectively (Lenschow et al., 2007; Morales and Lenschow,
476
477 2013). For all the genes, the baseline expression was recovered after 18h indicating a
478
479 transient effect of the flagellin.
480

481 The transcriptomic study was confirmed by testing the expression of the identified genes by
482
483 real time qPCR, in the lung at 2 and 4 h after intranasal instillation of flagellin (**Fig. 1A**). We
484
485 also analyzed the transcriptional response of the selected genes after systemic
486
487 administration of flagellin (**Fig. 1B**). Interestingly, the transcriptomic response for the
488
489 selected genes was globally similar between the two routes of administration,
490
491 demonstrating that a systemic administration of flagellin can activate antiviral genes in the
492
493 lung tissue. We also observed (i) a reduced variation in the gene expression after the
494
495 systemic route compared to the intranasal route and (ii) a peak expression at 4h post-
496
497 flagellin administration thus confirming the transcriptomic analysis. As expected, flagellin
498
499 was able to stimulate >50-fold expression of *Ccl20* and *Saa3*, surrogate markers of effective
500
501 stimulation of lung innate immunity by flagellin (Van Maele et al., 2010).
502
503

504 **Systemic and mucosal flagellin treatment induces a decrease of influenza genomic** 505 506 **RNA levels** 507

508 We then tested in an experimental model of infection whether the flagellin-mediated antiviral
509
510 transcriptomic response was associated with a decrease in IAV replication in the lung. The
511
512 model consists of the intranasal inoculation of mice with a sublethal dose of H3N2 influenza
513
514 A virus (IAV, 30 PFU), combined with intranasal treatments with 5 µg of flagellin (or PBS as
515
516 control intervention) every 24 h, starting 12 h prior infection (**Fig. 2A**). Viral replication was
517
518 followed by measuring the RNA levels of M1 genomic RNA in lung homogenates at 24, 48
519
520 and 96 h post-infection, through absolute quantification using Taqman-based real time PCR
521
522 with a calibrating curve. We found an increase in H3N2 M1 RNA levels from 24 to 96 h post-
523
524 infection, hence indicating efficient viral replication (**Fig. 2B**). At 48 h post-infection, the level
525
526 of M1 RNA copies in lung of flagellin-treated animals was 7.3 fold lower than in mice
527
528 receiving PBS, indicating an effect of the flagellin on the viral RNA replication. A similar yet
529
530
531

532
533
534 milder trend (2.3 fold decrease compared to PBS-treated mice) was also observed at 96 h
535
536 post-infection (**Fig. 2B**).

537
538 As flagellin showed antiviral properties through the systemic route (Zhang et al., 2014;
539 Hossain et al., 2014), we also treated the H3N2-infected animals with 5 µg of flagellin
540 through the intraperitoneal route (**Fig. 2C**). Interestingly, when IAV-infected animals were
541 treated by flagellin, we observed an 18.3 fold decrease on viral RNA levels at 48 h post-
542 infection compared to the PBS-treated group. A significant decrease (1.9 fold) of the M1
543 RNA levels was also observed at 96 h post-infection in the flagellin-treated group. These
544 results indicate that systemic administration of flagellin has a stronger effect on viral
545 replication than intranasal administration.

555 **The decrease of viral RNA levels upon flagellin administration is independent of** 556 **type I interferon signaling**

557
558 Most of the genes identified in the transcriptomic study (**Table 2**) are under the control of
559 type I interferon (IFN α and IFN β), therefore suggesting a role of these interferons in the
560 flagellin-mediated effect. To assess the putative role of type I IFN signaling, the levels of
561 viral RNA were quantified after flagellin treatment in mice deficient in the type I interferon
562 receptor (*Ifnar*^{-/-}). These mice were infected by IAV H3N2 and treated with flagellin by
563 systemic administration before monitoring viral RNA in lungs as mentioned before (**Fig. 2A**).
564 Flagellin induced significant 3.6 and 9 fold decrease of IAV M1 RNA at 48 and 96 h,
565 respectively (**Fig. 3**). These results show that type I IFN signaling is not required for the
566 flagellin-mediated reduction of IAV replication. This is also consistent with microarray data
567 that did not indicate any upregulation of IFN α - or IFN β -specific transcripts in the lungs of
568 flagellin-treated animals (<http://mace.ihes.fr>, accession no. 2176499768). Furthermore,
569 systemic or respiratory administration of flagellin did not increase the pulmonary expression
570 of *Ifnl2* or *Ifnl3* coding for type III IFN that were previously associated with influenza virus
571 clearance in mice (data not shown) (Mordstein et al., 2008). Altogether, these results

591
592
593 strongly suggest that interferons are not associated with the flagellin-mediated antiviral
594
595 effect.
596
597
598

599 **The effect of flagellin on viral RNA replication is independent of interleukin 22 (IL-22)**

600 Flagellin has previously been shown to protect against rotavirus intestinal infection through
601 production of IL-22 together with IL-18 (Zhang et al., 2014). First, we found that flagellin did
602 not stimulate *Il18* transcription in the lungs after intraperitoneal administration of flagellin
603 both in naive and IAV-infected animals, thus ruling out the possible role of IL-18 in flagellin-
604 mediated anti-IAV effect (**Supplementary Fig.**). We next evaluated the role of IL-22 upon
605 flagellin-administration in the IAV respiratory infection context. We first showed that
606 systemic administration of flagellin induced a strong production of IL-22 in the blood 2 h
607 post administration both in non-infected and H3N2-infected animals (**Fig. 4A-B**). Strong
608 expression of *Il22* was also observed in the lungs of naïve mice treated with flagellin
609 (**Supplementary Fig.**). The contribution of IL-22 in the flagellin-mediated anti-viral effect
610 was then analyzed in *Il22*^{-/-} mice by measuring the levels of viral RNA at 48 h post infection
611 after flagellin treatments (**Fig. 4A**). As in IL-22 proficient mice, IAV RNA levels were
612 significantly lower (7.5 fold decrease) in flagellin-treated *Il22*^{-/-} mice than in PBS-receiving
613 *Il22*^{-/-} mice (**Fig. 4C**). These results indicate that IL-22, which is produced upon flagellin
614 stimulation, is not required for the effect of flagellin on viral RNA production.
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649

Systemic administration of flagellin boosts the anti-viral effect of oseltamivir

We then investigated whether the reduction of viral RNA induced by flagellin could be improved by combination with a specific virus-targeted antiviral drug such as the neuraminidase inhibitor oseltamivir. This first line antiviral agent is recommended as *per os* administration to populations exposed to IAV-infected individuals for either prophylaxis and/or therapy. Mice were treated 12 h prior H3N2 infection and then 12 and 36 h post infection with either flagellin, oseltamivir or a combination of both compounds. A group of mice received PBS as untreated control. Viral RNA replication and virus production were analyzed 48h post viral challenge (**Fig. 5A**). First, we found that flagellin treatment statistically decreased the infectious virus titer by 4.5 fold thus confirming the impact of flagellin on the viral RNA levels (**Fig. 5B, C**). Interestingly, 5 µg of intranasal flagellin was as efficient as 4 mg/ml of oral oseltamivir to control the RNA replication and IAV production. The combination of flagellin and oseltamivir significantly reduced the levels of viral RNA and viral infectious particles by 38 and 163 fold, respectively, compared to untreated animals (**Fig. 5B, C**). The combination therapy is also more effective at reducing RNA replication than flagellin or oseltamivir standalone treatments. We did not observe any significant reduction of the infectious particles with the combination therapy compared to the standalone treatments. However, in 50% of flagellin + oseltamivir-treated animals, PFU numbers were below the limit of detection compared to 28 % for the oseltamivir group and 0% for the flagellin group. These results suggest that a combination of flagellin and oseltamivir may enhance the antiviral effect of each compound taken separately.

DISCUSSION

Immunomodulation targeting TLR signaling represents a promising approach to control infectious diseases (Savva and Roger, 2013; Hedayat et al., 2011; Mifsud et al., 2014). In the present study, we showed for the first time that treatment of mice with the TLR5 agonist

709
710
711 flagellin alters influenza virus replication in the lung, independently of the route of
712 administration (systemic or respiratory). We know from several infectious models that the
713 biological effect of flagellin is at least in part dependent on the administration route (Vijayan
714 et al., 2018): mucosal administration rather stimulates the epithelium, resulting in the
715 recruitment of neutrophils and the production of antimicrobial molecules, while a systemic
716 treatment activates dendritic cells that lead to the activation of T helper and type 3 innate
717 lymphoid cells.
718
719

720
721 Nevertheless, the mechanism by which flagellin reduces influenza replication is yet
722 unknown. As flagellin mainly affects viral RNA production, one can speculate that the TLR5
723 agonist affects the genomic transcription and replication of the influenza virus. Replication
724 of IAV is a complex mechanism involving many host factors (Villalon-Letelier et al., 2017).
725 It would be relevant to know whether these molecules are modulated upon flagellin
726 stimulation and what stage(s) of the viral RNA production is impacted by flagellin (negative-
727 sense viral RNA replication, complementary positive sense RNA production or viral RNA
728 transcription).
729
730

731
732 Our results also reinforced the proof-of-concept that flagellin is able to trigger antiviral
733 defenses (Zhang et al., 2014; Hossain et al., 2014). Hossain et al. showed in a model of
734 liver colonization by the murine CMV that the decrease of viral load by flagellin correlated
735 with the presence of NK cells suggesting a major role of these cells (Hossain et al., 2014).
736 A detailed analysis of pulmonary cellular populations is required to evaluate the participation
737 of NK cells but also other immune cells in flagellin-mediated control of IAV replication. In
738 the case of rotavirus intestinal infection, Zhang et al. demonstrated that IL-22 was required
739 for flagellin-mediated protection (Zhang et al., 2014). IL-22 is involved in host defense
740 mechanisms at the respiratory and intestinal mucosal surfaces and is produced after
741 systemic administration of flagellin in mice. (Van Maele et al., 2010; Van Maele et al., 2014b;
742 Kinnebrew et al., 2012). In our study, although we confirmed the IL-22 production after
743 flagellin administration, IL-22-deficient mice still managed to reduce M1 RNA upon flagellin
744 treatment, indicating that this cytokine was dispensable for the antiviral effect of flagellin.
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767

768
769
770 These results are in accordance with prior studies showing that IL-22, produced in the blood
771 and lungs during IAV infection, is not involved in the control of the IAV replication (Guo and
772 Topham, 2010; Ivanov et al., 2013).

773
774
775 Surprisingly, we also demonstrated that the effect of flagellin on viral replication was
776 independent of type I IFN, yet recognized as the main first line of defense against viruses.
777
778 This type I IFN independent anti-influenza response was also demonstrated with TLR2
779 agonists as well as with the association of TLR2/6 and TLR9 agonists, hence suggesting
780 that antiviral pathways induced through stimulation of these TLRs and TLR5 are
781 independent of the canonical IFN response (Tan et al., 2012; Tuvim et al., 2012).
782
783 Nevertheless, we found that flagellin activates several interferon-stimulated genes (ISG),
784 which may indicate the possibility of a TLR5-dependent, interferon-independent activation
785 of these genes.
786
787

788
789 We previously showed that administration of flagellin through the respiratory tract could
790 improve the therapeutic index of antibiotics in the context of pneumococcal infection and
791 post-IAV bacterial pneumonia (Porte et al., 2015). Here, we demonstrated that the
792 combination of flagellin and oseltamivir strongly decreases the level of viral M1 RNA,
793 significantly enhancing the antiviral effect of each standalone treatment. In that regard, the
794 effect of a therapy combining a TLR agonist and a specific influenza-targeted antiviral
795 molecule like oseltamivir has been described elsewhere. Indeed, Lau et al. showed that co-
796 administration of TLR3 agonist with oseltamivir reduced pulmonary viral titers of mice
797 infected with H5N1 virus, compared to oseltamivir alone (Lau et al., 2010). More recently,
798 Leiva-Suarez et al. reported that aerosol administration of TLR2/6 and TLR9 agonists
799 associated with oseltamivir improved mouse survival after lethal influenza A pneumonia
800 (Leiva-Juarez et al., 2018). Altogether, our data contribute to highlight the therapeutic
801 potential of the association of molecules with distinct modes of action : a neuraminidase
802 inhibitor with a direct effect on viral infectivity but with a narrow therapeutic window, and
803 stimulators of innate immunity acting on host cells by inducing antiviral pathways with longer
804 lasting effect.
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826

827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885

ACKNOWLEDGMENTS

This work was funded by INSERM, CNRS, Institut Pasteur de Lille, University of Lille and Inserm-Transfert (CoPoC grant “Innatebiotic”). We thank Dr R. Le Goffic for providing the plasmid used for the viral RNA quantification.

886
887
888 **REFERENCES**
889
890
891

- 892 Barjesteh, N., Shojadoost, B., Brisbin, J. T., Emam, M., Hodgins, D.C., Nagy, E., Sharif, S.,
893 2015. Reduction of avian influenza virus shedding by administration of Toll-like receptor
894 ligands to chickens. *Vaccine* 33, 4843-9.
895
896 Blanc, M., Hsieh, W.Y., Robertson, K.A., Kropp, K.A., Forster, T., Shui, G., Lacaze, P.,
897 Watterson, S., Griffiths, S.J., Spann, N.J., Meljon, A., Talbot, S., Krishnan, K., Covey,
898 D.F., Wenk, M.R., Craigon, M., Ruzsics, Z., Haas, J., Angulo, A., Griffiths, W.J., Glass,
899 C.K., Wang, Y., Ghazal, P., 2013. The transcription factor STAT-1 couples macrophage
900 synthesis of 25-hydroxycholesterol to the interferon antiviral response. *Immunity* 38, 106-
901 18.
902
903 Brass, A.L., Huang, I.C., Benita, Y., John, S.P., Krishnan, M.N., Feeley, E.M., Ryan, B.J.,
904 Weyer, J.L., van der Weyden, L., Fikrig, E., Adams, D.J., Xavier, R.J., Farzan, M.,
905 Elledge, S.J., 2009. The IFITM proteins mediate cellular resistance to influenza A H1N1
906 virus, West Nile virus, and dengue virus. *Cell* 139, 1243-54.
907
908 Collazo, C.M., Yap, G.S., Sempowski, G.D., Lusby, K.C., Tessarollo, L., Vande Woude,
909 G.F., Sher, A., Taylor, G.A., 2001. Inactivation of LRG-47 and IRG-47 reveals a family
910 of interferon gamma-inducible genes with essential, pathogen-specific roles in resistance
911 to infection. *J Exp Med* 194, 181-8.
912
913 Conrady, C.D., Zheng, M., Fitzgerald, K.A., Liu, C., Carr, D.J., 2012. Resistance to HSV-1
914 infection in the epithelium resides with the novel innate sensor, IFI-16. *Mucosal Immunol*
915 5, 173-83.
916
917 Didierlaurent, A., Goulding, J., Patel, S., Snelgrove, R., Low, L., Bebien, M., Lawrence, T.,
918 van Rijt, L.S., Lambrecht, B.N., Sirard, J.C., Hussell, T., 2008. Sustained desensitization
919 to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. *J*
920 *Exp Med* 205, 323-9.
921
922 Fiore, A.E., Fry, A., Shay, D., Gubareva, L., Bresee, J.S., Uyeki, T. M., 2011. Antiviral
923 agents for the treatment and chemoprophylaxis of influenza --- recommendations of the
924 Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 60, 1-24.
925
926 Fougerson, D., Van Maele, L., Songhet, P., Cayet, D., Hot, D., Van Rooijen, N., Mollenkopf,
927 H.J., Hardt, W.D., Benecke, A.G., Sirard, J.C., 2015. Indirect Toll-like receptor 5-
928 mediated activation of conventional dendritic cells promotes the mucosal adjuvant
929 activity of flagellin in the respiratory tract. *Vaccine* 33, 3331-41.
930
931 Furuse, Y., Suzuki, A., Kamigaki, T., Oshitani, H., 2009. Evolution of the M gene of the
932 influenza A virus in different host species: large-scale sequence analysis. *Virol J* 6, 67.
933
934
935
936
937
938
939
940
941
942
943
944

- 945
946
947 Govorkova, E.A., Baranovich, T., Seiler, P., Armstrong, J., Burnham, A., Guan, Y., Peiris,
948 M., Webby, R.J., Webster, R.G., 2013. Antiviral resistance among highly pathogenic
949 influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued
950 monitoring. *Antiviral Res* 98, 297-304.
951
952
953 Guo, H. and Topham, D.J., 2010. Interleukin-22 (IL-22) production by pulmonary Natural
954 Killer cells and the potential role of IL-22 during primary influenza virus infection. *J Virol*
955 84, 7750-9
956
957
958 Hammerbeck, D.M., Burleson, G.R., Schuller, C.J., Vasilakos, J.P., Tomai, M., Egging, E.,
959 Cochran, F.R., Woulfe, S., Miller, R.L., 2007. Administration of a dual toll-like receptor 7
960 and toll-like receptor 8 agonist protects against influenza in rats. *Antiviral Res* 73, 1-11.
961
962 Hancock, R.E., Nijnik, A., Philpott, D.J., 2012. Modulating immunity as a therapy for
963 bacterial infections. *Nat Rev Microbiol* 10, 243-54.
964
965 Hatakeyama, S., Sakai-Tagawa, Y., Kiso, M., Goto, H., Kawakami, C., Mitamura, K.,
966 Sugaya, N., Suzuki, Y., Kawaoka, Y., 2005. Enhanced expression of an alpha2,6-linked
967 sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation
968 of their sensitivity to a neuraminidase inhibitor. *J Clin Microbiol.* 43, 4139-46.
969
970 Hedayat, M., Netea, M.G., Rezaei, N., 2011. Targeting of Toll-like receptors: a decade of
971 progress in combating infectious diseases. *Lancet Infect Dis* 11, 702-12.
972
973 Horimoto, T., Kawaoka, Y., 2005. Influenza: lessons from past pandemics, warnings from
974 current incidents. *Nat Rev Microbiol* 3, 591-600.
975
976 Hossain, M.S., Ramachandiran, S., Gewirtz, A.T., Waller, E.K., 2014. Recombinant TLR5
977 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice. *PLoS One* 9,
978 e96165.
979
980 Huang, I.C., Bailey, C.C., Weyer, J.L., Radoshitzky, S.R., Becker, M.M., Chiang, J.J., Brass,
981 A.L., Ahmed, A.A., Chi, X., Dong, L., Longobardi, L.E., Boltz, D., Kuhn, J.H., Elledge,
982 S.J., Bavari, S., Denison, M.R., Choe, H., Farzan, M., 2011. Distinct patterns of IFITM-
983 mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. *PLoS*
984 *Pathog* 7, e1001258.
985
986
987
988 Ivanov, S., Renneson, J., Fontaine, J., Barthelemy, A., Paget, C., Fernandez, E.M., Blanc,
989 F., De Trez, C., Van Maele, L., Dumoutier, L., Huerre, M.R., Eberl, G., Si-Tahar, M.,
990 Gosset, P., Renauld, J.C., Sirard, J.C., Faveeuw, C., Trottein, F., 2013. Interleukin-22
991 reduces lung inflammation during influenza A virus infection and protects against
992 secondary bacterial infection. *J Virol* 87, 6911-24.
993
994
995 Iwasaki, A., Pillai, P.S., 2014. Innate immunity to influenza virus infection. *Nat Rev Immunol*
996 14, 315-28.
997
998 Jarchum, I., Liu, M., Lipuma, L., Pamer, E.G., 2011. Toll-like receptor 5 stimulation protects
999 mice from acute *Clostridium difficile* colitis. *Infect Immun* 79, 1498-503.
1000
1001
1002
1003

- 1004
1005
1006 Jiang, T., Zhao, H., Li, X.F., Deng, Y.Q., Liu, J., Xu, L.J., Han, J.F., Cao, R.Y., Qin, E.D.,
1007 Qin, C.F., 2011. CpG oligodeoxynucleotides protect against the 2009 H1N1 pandemic
1008 influenza virus infection in a murine model. *Antiviral Res* 89, 124-6.
1009
1010 Kawai, T., Akira, S., 2010. The role of pattern-recognition receptors in innate immunity:
1011 update on Toll-like receptors. *Nat Immunol* 11, 373-84.
1012
1013 Kinnebrew, M.A., Ubeda, C., Zenewicz, L.A., Smith, N., Flavell, R.A., Pamer, E.G., 2010.
1014 Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-
1015 resistant *Enterococcus* infection. *J Infect Dis* 201, 534-43.
1016
1017 Kinnebrew, M.A., Buffie, C.G., Diehl, G.E., Zenewicz, L.A., Leiner, I., Hohl, T.M., Flavell,
1018 R.A., Littman, D.R., Pamer, E.G., 2012. Interleukin 23 production by intestinal
1019 CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal
1020 innate immune defense. *Immunity* 36, 276-87.
1021
1022 Lau, Y.F., Tang, L.H., Ooi, E.E., Subbarao, K., 2010. Activation of the innate immune
1023 system provides broad-spectrum protection against influenza A viruses with pandemic
1024 potential in mice. *Virology* 406, 80-7.
1025
1026 Leiva-Juarez, M.M., Kirkpatrick, C.T., Gilbert, B.E., Scott, B., Tuvim, M.J., Dickey, B.F.,
1027 Evans, S.E., Markesich, D., 2018. Combined aerosolized Toll-like receptor ligands are
1028 an effective therapeutic agent against influenza pneumonia when co-administered with
1029 oseltamivir. *Eur J Pharmacol* 818, 191-197.
1030
1031 Lenschow, D.J., Lai, C., Frias-Staheli, N., Giannakopoulos, N.V., Lutz, A., Wolff, T., Osiak,
1032 A., Levine, B., Schmidt, R.E., Garcia-Sastre, A., Leib, D.A., Pekosz, A., Knobeloch, K.
1033 P., Horak, I., Virgin, H.W.t., 2007. IFN-stimulated gene 15 functions as a critical antiviral
1034 molecule against influenza, herpes, and Sindbis viruses. *Proc Natl Acad Sci U S A* 104,
1035 1371-6.
1036
1037 Liu, S.Y., Aliyari, R., Chikere, K., Li, G., Marsden, M.D., Smith, J.K., Pernet, O., Guo, H.,
1038 Nusbaum, R., Zack, J.A., Freiberg, A.N., Su, L., Lee, B., Cheng, G., 2013. Interferon-
1039 inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-
1040 hydroxycholesterol. *Immunity* 38, 92-105.
1041
1042 Meyer, L., Leymarie, O., Chevalier, C., Esnault, E., Moroldo, M., Da Costa, B., Georgeault,
1043 S., Roingeard, P., Delmas, B., Quere, P., Le Goffic, R., 2017. Transcriptomic profiling of
1044 a chicken lung epithelial cell line (CLEC213) reveals a mitochondrial respiratory chain
1045 activity boost during influenza virus infection. *PLoS One* 12, e0176355.
1046
1047 Mifsud, E.J., Tan, A. C., Jackson, D.C., 2014. TLR Agonists as Modulators of the Innate
1048 Immune Response and Their Potential as Agents Against Infectious Disease. *Front*
1049 *Immunol* 5, 79.
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062

- 1063
1064
1065 Mifsud, E.J., Tan, A.C., Reading, P.C., Jackson, D.C., 2016. Mapping the pulmonary
1066 environment of animals protected from virulent H1N1 influenza infection using the TLR-
1067 2 agonist Pam(2)Cys. *Immunol Cell Biol* 94, 169-76.
1068
1069 Morales, D.J., Lenschow, D.J., 2013. The antiviral activities of ISG15. *J Mol Biol* 425, 4995-
1070 5008.
1071
1072 Mordstein, M., Kochs, G., Dumoutier, L., Renauld, J. ., Paludan, S.R., Klucher, K., Staeheli,
1073 P., 2008. Interferon-lambda contributes to innate immunity of mice against influenza A
1074 virus but not against hepatotropic viruses. *PLoS Pathog* 4, e1000151.
1075
1076 Munoz, N., Van Maele, L., Marques, J.M., Rial, A., Sirard, J.C., Chabalgoity, J.A., 2010.
1077 Mucosal administration of flagellin protects mice from *Streptococcus pneumoniae* lung
1078 infection. *Infect Immun* 78, 4226-33.
1079
1080 Nempont, C., Cayet, D., Rumbo, M., Bompard, C., Villeret, V., Sirard, J.C., 2008. Deletion
1081 of flagellin's hypervariable region abrogates antibody-mediated neutralization and
1082 systemic activation of TLR5-dependent immunity. *J Immunol* 181, 2036-43.
1083
1084 Norton, E.B., Clements, J.D., Voss, T.G., Cardenas-Freytag, L., 2010. Prophylactic
1085 administration of bacterially derived immunomodulators improves the outcome of
1086 influenza virus infection in a murine model. *J Virol* 84, 2983-95.
1087
1088 Paget, C., Ivanov, S., Fontaine, J., Renneson, J., Blanc, F., Pichavant, M., Dumoutier, L.,
1089 Ryffel, B., Renauld, J.C., Gosset, P., Gosset, P., Si-Tahar, M., Faveeuw, C., Trottein, F.,
1090 2012. Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza
1091 A virus infection: potential role in protection against lung epithelial damages. *J Biol Chem*
1092 287, 8816-29.
1093
1094 Porte, R., Fougeron, D., Munoz-Wolf, N., Tabareau, J., Georgel, A.F., Wallet, F., Paget, C.,
1095 Trottein, F., Chabalgoity, J.A., Carnoy, C., Sirard, J.C., 2015. A Toll-Like Receptor 5
1096 Agonist Improves the Efficacy of Antibiotics in Treatment of Primary and Influenza Virus-
1097 Associated Pneumococcal Mouse Infections. *Antimicrob Agents Chemother* 59, 6064-
1098 72.
1099
1100 Rossman, J.S., Lamb, R.A., 2011. Influenza virus assembly and budding. *Virology* 411,
1101 229-36.
1102
1103 Savva, A., Roger, T., 2013. Targeting toll-like receptors: promising therapeutic strategies
1104 for the management of sepsis-associated pathology and infectious diseases. *Front*
1105 *Immunol* 4, 387.
1106
1107 Tan, A.C., Mifsud, E.J., Zeng, W., Edenborough, K., McVernon, J., Brown, L.E., Jackson,
1108 D. C., 2012. Intranasal administration of the TLR2 agonist Pam2Cys provides rapid
1109 protection against influenza in mice. *Mol Pharm* 9, 2710-8.
1110
1111 Tuvim, M.J., Gilbert, B.E., Dickey, B.F., Evans, S.E., 2012. Synergistic TLR2/6 and TLR9
1112 activation protects mice against lethal influenza pneumonia. *PLoS One* 7, e30596.
1113
1114
1115
1116
1117
1118
1119
1120
1121

- 1122
1123
1124 Van Maele, L., Carnoy, C., Cayet, D., Songhet, P., Dumoutier, L., Ferrero, I., Janot, L.,
1125 Erard, F., Bertout, J., Leger, H., Sebbane, F., Benecke, A., Renauld, J.C., Hardt, W.D.,
1126 Ryffel, B., Sirard, J.C., 2010. TLR5 signaling stimulates the innate production of IL-17
1127 and IL-22 by CD3(neg)CD127+ immune cells in spleen and mucosa. *J Immunol* 185,
1128 1177-85.
1129
1130
1131 Van Maele, L., Fougeron, D., Janot, L., Didierlaurent, A., Cayet, D., Tabareau, J., Rumbo,
1132 M., Corvo-Chamaillard, S., Boulenouar, S., Jeffs, S., Vande Walle, L., Lamkanfi, M.,
1133 Lemoine, Y., Erard, F., Hot, D., Hussell, T., Ryffel, B., Benecke, A.G., Sirard, J.C., 2014a.
1134 Airway structural cells regulate TLR5-mediated mucosal adjuvant activity. *Mucosal*
1135 *Immunol* 7, 489-500.
1136
1137
1138 Van Maele, L., Carnoy, C., Cayet, D., Ivanov, S., Porte, R., Deruy, E., Chabalgoity, J.A.,
1139 Renauld, J.C., Eberl, G., Benecke, A.G., Trottein, F., Faveeuw, C., Sirard, J.C., 2014b.
1140 Activation of Type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during
1141 *Streptococcus pneumoniae* infection. *J Infect Dis* 210, 493-503.
1142
1143
1144 Vijayan, A., Rumbo, M., Carnoy, C., Sirard, J.C., 2018. Compartmentalized Antimicrobial
1145 Defenses in Response to Flagellin. *Trends Microbiol* 26, 423-435.
1146
1147
1148 Villallon-Letelier, F., Brooks, A. G., Saunders, P.M., Londrigan, S.L., Reading, P.C., 2017.
1149 Host Cell Restriction Factors that Limit Influenza A Infection. *Viruses* 9.
1150
1151 Wang, X., Hinson, E.R., Cresswell, P., 2007. The interferon-inducible protein viperin inhibits
1152 influenza virus release by perturbing lipid rafts. *Cell Host Microbe* 2, 96-105.
1153
1154 Wong, J.P., Christopher, M.E., Viswanathan, S., Karpoff, N., Dai, X., Das, D., Sun, L.Q.,
1155 Wang, M., Salazar, A. M., 2009. Activation of toll-like receptor signaling pathway for
1156 protection against influenza virus infection. *Vaccine* 27, 3481-3.
1157
1158 Wu, C.C., Hayashi, T., Takabayashi, K., Sabet, M., Smee, D.F., Guiney, D.D., Cottam, H.
1159 B., Carson, D.A., 2007. Immunotherapeutic activity of a conjugate of a Toll-like receptor
1160 7 ligand. *Proc Natl Acad Sci U S A* 104, 3990-5.
1161
1162 Yu, F.S., Cornicelli, M.D., Kovach, M.A., Newstead, M.W., Zeng, X., Kumar, A., Gao, N.,
1163 Yoon, S.G., Gallo, R.L., Standiford, T.J., 2010. Flagellin stimulates protective lung
1164 mucosal immunity: role of cathelicidin-related antimicrobial peptide. *J Immunol* 185,
1165 1142-9.
1166
1167
1168 Zhang, B., Chassaing, B., Shi, Z., Uchiyama, R., Zhang, Z., Denning, T.L., Crawford, S. E.,
1169 Pruijssers, A.J., Iskarpatyoti, J.A., Estes, M.K., Dermody, T.S., Ouyang, W., Williams,
1170 I.R., Vijay-Kumar, M., Gewirtz, A.T., 2014. Viral infection. Prevention and cure of
1171 rotavirus infection via TLR5/NLRC4-mediated production of IL-22 and IL-18. *Science*
1172 346, 861-5.
1173
1174
1175
1176
1177
1178
1179
1180

1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239

Zhao, J., Wohlford-Lenane, C., Zhao, J., Fleming, E., Lane, T.E., McCray, P.B., Jr.,
Perlman, S., 2012. Intranasal treatment with poly(I*C) protects aged mice from lethal
respiratory virus infections. *J Virol* 86, 11416-24.

FIGURE LEGENDS

Figure 1: Intranasal or systemic administration of flagellin activates antiviral genes in the lung. C57BL/6 male mice (n=4) were treated intranasally (A) or intraperitoneally (B) with 5 µg of flagellin in phosphate-buffered saline. Lungs were sampled at 2h and 4h and mRNA was quantified by qRT-PCR. Relative expression was normalized to the expression of mock animals (arbitrarily set to a value of 1). Results are represented as the mean. Statistical significance relative to mock group was assessed by one-way ANOVA with Dunnett's multiple comparison test (*: P <0,05 ; **: P <0,01, ***: P <0.001)

Figure 2: Systemic and mucosal administration of flagellin altered viral RNA replication in the lung.

(A) Male C57BL/6 mice (n=5 to 6) were infected intranasally with H3N2 (30 PFU). Twelve hours before infection and 12, 36, 60 and 84 h post-infection, mice received 5 µg of flagellin intranasally (B) or intraperitoneally (C). Lungs were sampled 24, 48 or 96 h post infection for viral RNA quantification using quantitative RT-PCR. Values correspond to the absolute copy number of the M1 viral RNA / 12.5 ng of total lung RNA. The solid line corresponds to the median value and the dashed line represents the detection threshold. A representative experiment out of two is shown. Statistical significance was assessed by Mann-Whitney test (**: P <0,01).



Figure 3: The type I interferon pathway is not required for the flagellin-mediated effect on viral RNA production. *Ifnar*^{-/-} mice (n=4 to 6) were infected intranasally with H3N2 (30 PFU) and treated intraperitoneally with 5 µg of flagellin twelve hours before infection and 12, 36, 60 and 84 h post-infection. Lungs were sampled 48 and 96 h post infection for viral RNA quantification using quantitative RT-PCR. Values correspond to the absolute copy number of the M1 viral RNA / 12.5 ng of total lung RNA. The solid line corresponds to the




1299
1300
1301 median value and the dashed line represents the detection threshold. Statistical significance
1302 was assessed by Mann-Whitney test (*: P <0.05 ; **: P <0.01)
1303
1304


1305
1306 **Figure 4 : IL-22 is not required for flagellin-mediated decrease of viral H3N2 M1 RNA**
1307 **levels.** (A) Male C57BL/6 or *Il22*^{-/-} mice (n = 7) were infected intranasally with H3N2 (30
1308 PFU). Twelve hours before infection and 12 and 36h post-infection, mice received
1309 intraperitoneally 5 µg of flagellin or PBS as control. (B) Blood was sampled in C57BL/6 mice
1310 10 h before infection and 38 h post-viral challenge for serum cytokine analysis. IL-22 levels
1311 in serum were measured by ELISA. Results are given as mean with standard deviation. As
1312 expected IL-22 was not detected in *Il22*^{-/-} mice (data not shown). Statistical significance (**:
1313 P <0.01) compared to PBS-treated group was assessed by Mann-Whitney test. (C) Lungs
1314 were sampled at 48 h post-infection for viral RNA quantification using quantitative RT-PCR.
1315 Values correspond to the absolute copy number of M1 viral RNA / 12.5 ng of total lung RNA.
1316 The solid line corresponds to the median value and the dashed line represents the detection
1317 threshold. One representative experiment out of two is shown. Statistical significance was
1318 assessed by Mann-Whitney test (**: P <0.01, ***: P <0.001).
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332




1333 **Figure 5 : Systemic administration of flagellin boosts the effect of oseltamivir**




1334 (A) Male C57BL/6 mice (n = 11) were infected intranasally with H3N2 (30 PFU). Twelve
1335 hours before infection and 12 and 36 h post-infection, mice received either 5 µg of flagellin
1336 intraperitoneally, 4 mg/kg of oseltamivir (OSL 4) intragastrically, or a combination of flagellin
1337 with oseltamivir. A group of mice was left untreated (PBS). Lungs were sampled 48 h post
1338 infection. (B) Viral RNA quantification using quantitative RT-PCR. Values correspond to the
1339 absolute copy number of M1 viral RNA / 12.5 ng of total lung RNA. (C) Infectious viral titers
1340 defined as plaque forming units (PFU) / g of lung tissue. The solid line corresponds to the
1341 median value. The dashed line represents the detection threshold. Statistical significance
1342 was assessed by Mann-Whitney test (*: P <0.05; **: P <0.01; ***: P <0.001).
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357














Supplementary figure: Flagellin treatment does not activate expression of IL-18 encoding gene. (A) C57BL/6 mice ($n=4$) were treated intraperitoneally with 5 μg of flagellin in PBS. Lungs were sampled at 2h and 4h and mRNA was quantified by RT-qPCR. (C) C57BL/6 mice ($n=5$ to 6) were infected intranasally with H3N2 (30 PFU). Twelve hours before infection and 12 and 36h post-infection, mice received 5 μg of flagellin intraperitoneally. Lungs were sampled 24 and 48 h post-infection (12h post-flagellin administration) and mRNA was quantified by RT-qPCR. (B, D) The relative gene expression was normalized to the expression of PBS-treated animals (arbitrarily set to a value of 1. Results are represented as the median with standard deviation.

Table 1 : Antiviral canonical pathways up-regulated by flagellin

Canonical pathways	p-values ^a		
	2h	4h	18h
Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses	3.55 10 ⁻⁹	7.08 10 ⁻¹⁰	7.24 10 ⁻⁴
Activation of IRF by Cytosolic Pattern Recognition Receptors	4.68 10 ⁻⁷	3.31 10 ⁻⁹	4.92 10 ⁻¹
Role of PKR in Interferon Induction and Antiviral Response	1.02 10 ⁻⁶	7.94 10 ⁻¹²	2.30 10 ⁻²
Role of RIG1-like Receptors in Antiviral Innate Immunity	3.63 10 ⁻⁶	9.33 10 ⁻⁶	1.12 10 ⁻¹
NF-κB Activation by Viruses	6.76 10 ⁻³	1.29 10 ⁻⁶	1.82 10 ⁻⁴

^a Whole-genome expression microarrays were performed using lungs from C57BL/6 mice (n=3-5 per group) that were treated intranasally with flagellin for 2h, 4h and 18h and compared to mock-treated mice (<http://mace.ihes.fr>; accession no. **2176499768**) (Fougeron, et al., 2015). After NeoNORM analysis, the gene lists containing group means of expression, p-values and standard fold changes were utilized as input for analysis of canonical pathways with Ingenuity Pathway Analysis 1.0 software (IPA, Ingenuity Systems).

Table 2 : Intranasal administration of flagellin induces the transcription of anti-viral genes in the lung

Gene ID	Gene symbol	Gene name	Fold increase ^a		
			2h	4h	18h
12642	<i>Ch25h</i>	cholesterol 25-hydroxylase	13.44	12.42	2.88
875318	<i>Ifi204</i>	interferon gamma-inducible protein 16	4.64	7.07	< 2
213002	<i>Ifitm6</i>	interferon induced transmembrane protein 6	4.23	7.82	< 2
73835	<i>Ifitm5</i>	interferon induced transmembrane protein 5	3.24	3.45	< 2
15953	<i>Ifi47</i>	interferon gamma inducible protein 47	3.08	4.42	< 2
58185	<i>Rsad2</i>	radical S-adenosyl methionine domain containing 2	< 2	10.94	< 2
100038882	<i>Isg15</i>	ISG15 ubiquitin-like modifier	< 2	6.93	< 2

Whole-genome expression microarrays were performed using lungs from C57BL/6 mice (n=3-5 per group) that were treated intranasally with flagellin for 2h, 4h and 18h and compared to mock-treated mice (<http://mace.ihes.fr>; accession no. **2176499768**) (Fougeron, et al., 2015). ^a The fold increase values correspond to the differential expression of genes at the indicated time after flagellin stimulation compared to mock-treated condition.

Supplementary Table : Sequences of primers used for qRT-PCR

<i>β Actin</i>	Forward sequence : CGTCATCCATGGCGAACTG Reverse sequence : GCTTCTTTGCAGCTCCTTCGT
<i>Ccl20</i>	Forward sequence : TTTTGGGATGGAATTGGACAC Reverse sequence : TGCAGGTGAAGCCTTCAACC
<i>Ch25h</i>	Forward sequence : CCGGATCACATTACCTGGTC Reverse sequence : AAGACCTGGGCTGTTCCAG
<i>Ifi204</i>	Forward sequence : GCCAGCCCTAAGATCTGTGA Reverse sequence : TCTTTCGGTTCAGTCTTTTCTTG
<i>Ifi47</i>	Forward sequence : GCGTTTCCTCCATCTTCACT Reverse sequence : ACCGGGTCTGTTTCTCACTG
<i>Ifitm5</i>	Forward sequence : GGTCTGTCTTCAGCACGATG Reverse sequence : CAGCCATCTTCTGGTCTCG
<i>Ifitm6</i>	Forward sequence : CCGGATCACATTACCTGGTC Reverse sequence : CATGTCGCCACCATCTT
<i>Ifnb</i>	Forward sequence : CCTACAGGGCGGACTTCAAG Reverse sequence : GATGGCAAAGGCAGTGTA ACTCT
<i>Ifnl2</i>	Forward sequence : AGGTCTGGGAGAACATGACTG Reverse sequence : CTGTGGCCTGAAGCTGTGTA
<i>Ifnl3</i>	Forward sequence : TCAGCCCTGACCACCATC Reverse sequence : CTGTGGCCTGAAGCTGTGTA
<i>Il18</i>	Forward sequence : CAAACCTTCAAATCACTTCCT Reverse sequence : TCC-TTG-AAG-TTG-ACG-CAA-GA
<i>Isg15</i>	Forward sequence : AGTCGACCCAGTCTCTGACTCT Reverse sequence : CCCAGCATCTTACCTTTA
<i>Oasl1</i>	Forward sequence : GGTCATCGAGGCCTGTGT Reverse sequence : TGGGTCCAGGATGATAGGC
<i>Rsad2</i>	Forward sequence : GTGGACGAAGACATGAATGAAC Reverse sequence : TCAATTAGGAGGCACTGGAAA
<i>Saa3</i>	Forward sequence : GCCTGGGCTGCTAAAGTCAT Reverse sequence : TGCTCCATGTCCCGTGAA